drugset / Trial / NCT00258739
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
RandomizedParallel-groupOpen-labelTreatment
Summary
Primary objective: * To classify the 2 study groups, according to the tumoral response. Secondary objectives: * To evaluate the percentage of focused control per year. * To calculate the time until progression. * To evaluate the safety profile.
Timeline
- Start
- 2001-10
- Primary completion
- 2007-09
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 2 unknown | — |
| Subject | Docetaxel | Small molecule | 20 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 40 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1200 mg/m2 | — |